Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Iradimed Cp (IRMD)

Iradimed Cp (IRMD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 267,422
  • Shares Outstanding, K 11,370
  • Annual Sales, $ 30,440 K
  • Annual Income, $ 6,300 K
  • 60-Month Beta 1.60
  • Price/Sales 8.69
  • Price/Cash Flow 40.02
  • Price/Book 5.41

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 0.18
  • Number of Estimates 1
  • High Estimate 0.18
  • Low Estimate 0.18
  • Prior Year 0.14
  • Growth Rate Est. (year over year) +28.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.35 +8.48%
on 10/14/19
26.48 -12.54%
on 10/30/19
+1.48 (+6.83%)
since 10/11/19
3-Month
18.07 +28.17%
on 09/04/19
26.48 -12.54%
on 10/30/19
+1.50 (+6.93%)
since 08/12/19
52-Week
16.68 +38.85%
on 07/15/19
30.90 -25.05%
on 12/04/18
-2.23 (-8.78%)
since 11/12/18

Most Recent Stories

More News
IRadimed (IRMD) Q3 Earnings and Revenues Beat Estimates

iRadimed (IRMD) delivered earnings and revenue surprises of 53.33% and 1.15%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

IRMD : 23.60 (+0.34%)
IRADIMED CORPORATION Announces Third Quarter 2019 Financial Results

-- Reports third quarter 2019 revenue of $10.0 million, GAAP diluted EPS of $0.20 and non-GAAP diluted EPS of $0.23

IRMD : 23.60 (+0.34%)
IRADIMED CORPORATION to Hold 2019 Third Quarter Financial Results Conference Call on October 30th

IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2019 third quarter financial results before the market opens on Wednesday, October 30. IRADIMED management will host...

IRMD : 23.60 (+0.34%)
IRADIMED CORPORATION Resolves Warning Letter Related to Its Infusion Pump System

IRADIMED CORPORATION (NASDAQ: IRMD), today announced that it received a close-out letter from the U.S. Food and Drug Administration resolving all issues cited in the August 2014 warning letter.

IRMD : 23.60 (+0.34%)
IRADIMED CORPORATION to Participate in the Morgan Stanley 17th Annual Global Healthcare Conference

IRADIMED CORPORATION (NASDAQ: IRMD), today announced that Leslie McDonnell, President and Chief Executive Officer, Roger Susi, Chairman and Chief Technology Officer and Chris Scott, Chief Financial Officer,...

MS : 49.15 (+0.12%)
IRMD : 23.60 (+0.34%)
IRadimed (IRMD) Beats Q2 Earnings and Revenue Estimates

iRadimed (IRMD) delivered earnings and revenue surprises of 33.33% and 3.55%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

IRMD : 23.60 (+0.34%)
IRADIMED CORPORATION Announces Second Quarter 2019 Financial Results

-- Reports second quarter 2019 revenue of $9.2 million

IRMD : 23.60 (+0.34%)
IRADIMED CORPORATION Names Leslie McDonnell as President and Chief Executive Officer

IRADIMED CORPORATION (NASDAQ: IRMD) announced today that its Board of Directors unanimously appointed Leslie McDonnell, to succeed Roger Susi as President and Chief Executive Officer. Mr. Susi will step...

IRMD : 23.60 (+0.34%)
Shares of IRMD Down 26.8% Since Downtrend Call on Shares

SmarTrend identified a Downtrend for Iradimed Corp (NASDAQ:IRMD) on April 30th, 2019 at $26.31. In approximately 3 months, Iradimed Corp has returned 26.85% as of today's recent price of $19.25.

IRMD : 23.60 (+0.34%)
Iradimed Corp Shares Down 30.0% Since SmarTrend's Sell Call (IRMD)

SmarTrend identified a Downtrend for Iradimed Corp (NASDAQ:IRMD) on April 30th, 2019 at $26.32. In approximately 3 months, Iradimed Corp has returned 29.96% as of today's recent price of $18.43.

IRMD : 23.60 (+0.34%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More Share

Trade IRMD with:

Business Summary

iRadimed Corporation engages in developing, manufacturing, marketing, and distributing magnetic resonance imaging (MRI) compatible products. It offers non-magnetic intravenous (IV) infusion pump systems, IV tubing sets, IV poles, wireless remote displays/controls under the mRidium name; side car pump...

See More

Key Turning Points

2nd Resistance Point 24.04
1st Resistance Point 23.78
Last Price 23.60
1st Support Level 23.04
2nd Support Level 22.56

See More

52-Week High 30.90
Fibonacci 61.8% 25.47
Fibonacci 50% 23.79
Last Price 23.60
Fibonacci 38.2% 22.11
52-Week Low 16.68

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar